Hepatocellular Carcinoma
description
Transcript of Hepatocellular Carcinoma
![Page 1: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/1.jpg)
HEPATOCELLULAR CARCINOMA
![Page 2: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/2.jpg)
Epidemiology Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.
Worldwide, its prevalence follows that of hepatitis B and hepatitis C virus infection.
Incidence is highest in Asia and sub-Saharan Africa with as many as 120 cases per 100,000.1
relatively uncommon in Europe and North America
![Page 3: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/3.jpg)
…. HCC may be diagnosed more frequently over the next few years due to the hepatitis C epidemic.
3,2 HCC usually occurs 20-30 years after the initial liver insult.
The average age of development of HCC is 66 years.
![Page 4: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/4.jpg)
Causes liver cirrhosis - major risk factor in 90 to 95% of people who develop HCC
<Hepatitis B or hepatitis C infection. 350M have chronic hepatitis B.
Chronic hepatitis B infection is the most common cause of HCC worldwide.
170 M have hepatitis C hepatitis Cchronic infxn > B. Hepatitis C is the most common cause of HCC in Europe.
Hep B+C increases HCC risk further. Alcoholism. Genetic haemochromatosis. Primary biliary cirrhosis. High aflatoxins in food. metabolic syndrome related to obesity and diabetes is an important risk factor
![Page 5: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/5.jpg)
Rare associations include: 1Androgenic steroids Primary sclerosing cholangitis
Alpha-1-antitrypsin deficiency
Oral contraceptives Porphyria cutanea tarda
![Page 6: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/6.jpg)
MEN >WOMEN This is usually with symptoms of advancing cirrhosis and liver failure.
![Page 7: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/7.jpg)
SSymptoms
PruritusRight upper quadrant pain
![Page 8: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/8.jpg)
Signs Jaundice Abdominal distension due to ascites Jaundice Confusion and hepatic encephalopathy Bleeding oesophageal varices Hepatomegaly Cachexia Ascites Spider naevi Peripheral oedema Periumbilical collateral veins Asterixis
![Page 9: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/9.jpg)
Metastases can develop in the lung, portal vein, periportal nodes, bone or brain.
![Page 10: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/10.jpg)
1Who should be screened for hepatocellular carcinoma? cirrhosis < hepatitis B or C , or due to genetic haemochromatosis.
alcohol-related cirrhosis
cirrhosis <primary biliary cirrhosis (the risk of women developing HCC is low).
![Page 11: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/11.jpg)
Six-monthly screening with abdominal ultrasound and alpha-fetoprotein (AFP) was suggested.
![Page 12: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/12.jpg)
Screening tests for hepatocellular carcinoma
![Page 13: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/13.jpg)
The efficacy and cost-effectiveness of screening programmes for at-risk patients is unclear.
Note: lack of curative treatment options in all patients with cirrhosis.
![Page 14: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/14.jpg)
1Possible screening tests include:
AFP N= 10-20 ng/ml. >400 ng/ml -
CAVEATS on AFP 2/3of HCC <4 cm have AFP levels <200 ng/ml
Up to 20% of HCC do not produce AFP. F(+) High levels of AFP may be seen in regenerating nodules in viral cirrhosis
![Page 15: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/15.jpg)
ImagingUltrasound scan (USS)
can detect large lesions ;
less reliable for small lesions ;
is user-dependent. USS +AFP measurements - better screening tool.
![Page 16: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/16.jpg)
Diagnostic tests for hepatocellular carcinoma
A focal liver lesion in cirrhosis - highly likely HCC
If a >2 cm mass + Elev AFP diagnostic.
![Page 17: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/17.jpg)
Further investigation is only needed to determine the best treatment.3 CT of the liver can look for local spread and CT of the thorax can look for metastases.3
![Page 18: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/18.jpg)
MRI scanning with contrast or angiography with lipiodol injection with follow-up CT may also be used in assessment.
![Page 19: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/19.jpg)
Some sources state that seeding of tumour in the needle tract occurs in 1-3% of cases.
![Page 20: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/20.jpg)
Other investigations:
Alpha-fetoprotein is elevated in 75% of cases.
A level of >400 ng/ml may be regarded as diagnostic by some.
Liver function tests may be consistent with cirrhosis.
Check for clotting abnormalities.
Albumin may be low. Chest X-ray may show a raised right hemidiaphragm or lung metastases.
![Page 21: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/21.jpg)
Differential diagnosis
Cirrhosis Cholangio-carcinoma Primary lymphoma of the liver
Metastatic carcinoma (30 times as common in Europe as HCC)
![Page 22: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/22.jpg)
Staging
A number of staging systems have been developed.
Those that incorporate that state of liver function and the patient's clinical state (e.g. presence of ascites, portal vein involvement, etc.) as well as the tumour morphology, may be most useful.
![Page 23: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/23.jpg)
The Cancer of the Liver Italian Program (CLIP) scoring system is one of these.
![Page 24: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/24.jpg)
Child-Pugh stage - the Child-Pugh-Turcotte (CPT) classification system - widely-used and validated way to estimate prognosis in those with cirrhosis
Stage A = 0 Stage B = 1 Stage C = 2
![Page 25: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/25.jpg)
Tumour morphology:
Uninodular and extension less than 50% = 0
Multinodular and extension less than 50% = 1
Massive and extension greater than 50% = 2
![Page 26: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/26.jpg)
Alpha-fetoprotein:
Less than 400 = 0Greater than 400 = 1Portal vein thrombosis: Absent = 0 Present = 1
![Page 27: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/27.jpg)
Estimated survival based on CLIP score: Patients with a CLIP score of 0 have an estimated survival of 31 months;
those with score of 1, about 27 months
score of 2, 13 months;
score of 3, 8 months; and
scores 4-6, approximately 2 months.
![Page 28: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/28.jpg)
The Barcelona Clinic Liver Cancer (BCLC) staging and treatment approach
is another tool that is used by many for management.
![Page 29: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/29.jpg)
Management
Before treatment of the primary tumour, any complications of cirrhosis or liver failure must be treated. ascites, encephalopathy or spontaneous bacterial peritonitis and
oesophageal varices.
![Page 30: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/30.jpg)
Treatment options for HCC: depend on: 1The size, number and location of tumours.
The presence or absence of cirrhosis.
The operative risk based on extent of cirrhosis and co-morbid diseases.
The patient's overall performance status.
The patency of the portal vein
.Whether there is metastatic disease.
![Page 31: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/31.jpg)
Liver transplantation
Only about 5% of people with HCC are suitable for transplantation.
Single lesions of ≤5 cm diameter, or up to three lesions of ≤3 cm with no vascular invasion seen on imaging, have an almost zero recurrence rate after liver transplantation.
![Page 32: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/32.jpg)
Tumour resection In the short-term, resection produces similar results as transplantation but, at three years, there is a higher chance of tumour-free survival after transplantation.
Very good liver function needed if for resection. Decompensation possible after surgery.
Liver left behind after resection still has malignant potential and recurrence rates are 50-60% after five years.
![Page 33: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/33.jpg)
Ablative therapy - Alcohol (ethanol) injection - this is done percutaneously and has been carried out on small tumours in those with good underlying liver function.
Limited ablation success and high recurrence rates for Larger lesions
![Page 34: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/34.jpg)
Treatment - difficult in the posterior segments of the liver and needle tract tumour seeding is a risk, as well as bile duct injury.
This may be the best treatment for those with small, inoperable HCCs.3
![Page 35: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/35.jpg)
Radiofrequency ablation -
high frequency ultrasound probes are placed into the tumour mass.
relatively new technique that produces tumour necrosis.
It may be more effective than ethanol injection for larger tumours.
This procedure is approved by NICE.
![Page 36: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/36.jpg)
Microwave ablation -
this is approved by NICE.
It destroys tumour cells by heat and results in localised areas of necrosis and tissue destruction.
Needle electrodes are inserted into the liver, either percutaneously or at laparoscopy or laparotomy, and are attached to a microwave generator.9 Acetic acid, laser or cold ablation may also be used.
![Page 37: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/37.jpg)
Chemoembolisation delivery of high concentrations of chemotherapy drugs directly to the tumour via the hepatic artery using embolising agents such as cellulose.
used in those with preserved liver function with large or multifocal tumours without vascular invasion or extrahepatic spread, and who have no symptoms.
effective in reducing tumour size as well as treating pain or bleeding.
Median survival is >2 years
![Page 38: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/38.jpg)
Systemic chemotherapy
may be used in advanced disease but HCC is relatively chemotherapy-resistant.
Therapies with molecular targeted therapies, such as sorafenib, are also being investigated and are so far very promising.
Sorafenib is currently being assessed by NICE.
![Page 39: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/39.jpg)
Other treatments
Retinoids and adaptive immunotherapy (using primed peripheral lymphocytes)
CyberKnife® stereotactic radiosurgery is a new technology.
It combines robotics and image guidance so that highly focused, concentrated beams of radiation can be delivered to the tumour.
1 This is not widely available at present.
![Page 40: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/40.jpg)
Interferon treatment in chronic hepatitisTreatment of chronic hepatitis C can clear the virus in more than half of people treated.
![Page 41: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/41.jpg)
NICE recommends a combination therapy of pegylated interferon and ribavirin for the treatment of chronic hepatitis C.
![Page 42: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/42.jpg)
Prognosis - depends on the extent of underlying cirrhosis
Median survival ~ about 6 months.
Liver failure can occur with death < cachexia, variceal bleeding and, occasionally, tumour rupture with intraperitoneal bleeding.
![Page 43: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/43.jpg)
Surgical resection, liver transplantation and ablation by radiofrequency or ethanol injection are now conventional therapies for early stage disease.
![Page 44: Hepatocellular Carcinoma](https://reader036.fdocuments.in/reader036/viewer/2022062316/56816728550346895ddbc512/html5/thumbnails/44.jpg)
Prevention is the best approach. The hepatitis B vaccine will, it is hoped, reduce the incidence of HCC.2
There is so far no vaccine against hepatitis C but treatments including interferon alpha may have a beneficial effect.
A sensible approach to alcohol consumption would also be beneficial.